Publications by authors named "Domingo Saavedra"
Article Synopsis
- The study examined the clinical and survival characteristics of transplant-eligible multiple myeloma patients in Latin America, focusing on the differences between public and private healthcare systems.
- It included data from 1293 patients diagnosed from 2010 to 2018, highlighting significant disparities in outcomes and survival rates between those treated in public versus private institutions.
- The findings suggest that late diagnosis and limited access to effective treatments in public facilities contribute to poorer survival rates, while patients receiving modern therapies and autologous stem cell transplants have survival rates comparable to international standards.
Glivec (imatinib mesylate) has changed the natural history of chronic-phase chronic myeloid leukemia (CML-CP), transforming it into a long-term and manageable disease. At our institution, we treat over 100 patients with CML-CP per year, typically with first-line imatinib therapy. Recently, several healthcare systems and insurance providers have substituted non-branded versions of imatinib that have not demonstrated efficacy or safety comparable to that of imatinib.
View Article and Find Full Text PDF